Backers of Maryland’s stem cell ecosystem hope a federal judge’s ruling last week in a Florida case that the Food and Drug Administration can regulate stem cell treatments is the first step toward protecting their legitimacy. With comments from our Debra Mathews

Quick Read

In a decision expected to send a chill through the booming stem cell industry, a federal judge ruled in favor of the Food and Drug Administration on Monday in a lawsuit against a Florida-based stem cell company whose treatments have blinded at least four patients

Quick Read

ISSCR, an international stem-cell body says the country’s proposed law could put patients at risk

Quick Read

Our Jeffrey Kahn joins panelists at a symposium cohosted by the Berman Institute and the New York Stem Cell Foundation with support from the Stavros Niarchos Foundation. Watch now:

Quick Read

The FDA has taken an industry-friendly approach toward companies using unproven cell cocktails to treat people desperate for relief from aging or damaged joints

Quick Read

How well-meaning donations end up fueling an unproven, virtually unregulated $2 billion stem cell industry

Quick Read

Under a draft proposal, patients would be able to buy some therapies without regulatory approval

Quick Read

Join NYSCF and the Johns Hopkins Berman Institute of Bioethics on May 8, 6-8pm for an interactive discussion featuring Betsy Myers, PhD, Neville Sanjana, PhD, Susan L. Solomon, JD as well as Johns Hopkins bioethicist Jeffrey Kahn, PhD, MPH to explore the implications of gene editing for research, medicine, and humanity.

Quick Read